CPSI Receives US Patent Allowance on Cryomedical Injection Device

Patent Covers Next Generation Hand-Held Cryotreatment Systems and Method Of Use

June 3, 2013

OWEGO, NY -- CPSI Biotech announced today the issuance of a patent (US Pat#: 8,409,184) by the US Patent Office covering device design and method of use of a new advanced hand-held cryomedical-injection system platform. Patent coverage includes a medical injection device comprising one or more treatment pellets, an injection assembly for discharging the pellets, a cartridge providing storage for the treatment pellets and supplying pellets to the injection assembly, and an insertion needle dispensing site for placement of one or more of the treatment pellets into a targeted tissue.

"The cryomedical injection device and approach, which we refer to as the *CryoInject*™ and *CryoPellets*™ platform, offers the unique ability for the simultaneous application of cryotherapy and cytotoxic agent therapy in a novel delivery system. The *CryoInject*™ system enables the delivery or injection a frozen *CryoPellets*™ into a target tissue to produce a destructive treatment/freeze zone. The resorbable cryopellet technology offers the potential to decrease procedural related side effects, increase therapeutic efficacy, and reduce overall cost, ultimately leading to increased cryosurgical application to numerous other disease states." said Dr. J.M. Baust, President and Lead Scientist, CPSI Biotech.

When asked to elaborate on this technology looking forward, Dr. Baust stated "Though cryosurgery is a viable and growing alternative treatment modality, the current generation of cryodevices are large devices and require extended procedure times, protracted re-freezing, and freezing of a significant area beyond the disease margin to adequately destroy targeted tissue. In the treatment of prostate cancer, major anatomical structures, including the urethra, urinary bladder, rectal wall, and nerve bundles can be compromised resulting in secondary medical challenges to the patient (increased morbidity). Further, with the growth of focal therapy and evolution in the management of BPH, current devices and approaches are more complex, invasive, and more costly than necessary. Together, *CryoInject*™ and *CryoPellets*™, represent a major evolution in the development of medical devices by using self-contained cryogen pellets (seeds) that are injected into a target tissue generating a lesion and then are harmlessly resorbed into the body. The *CryoPellets*™, containing imbedded cryosensitization agents, are designed to deliver an efficient ablative insult to a defined region yielding precise focal ablation with minimal effect to surrounding tissue. The cryosensitization pellet approach requires only the generation of localized tissue temperatures of -10°C or lower to completely destroy the cancer calls. At less than a few minutes for insertion and lesion creation, the *CryoInject*™ system will reduce procedure time, costs, and complication risks without sacrificing efficacy. The ability to generate rapid, highly lethal lesions at mild subfreezing temperatures in a cost effective, minimally invasive, *in situ* format provides novelty for the *CryoInject*™ platform that is compatible with numerous medical specialties and the potential for treating numerous cancers."

When asked about the potential market for the *CryoInject*™ and *CryoPellets*™ platform, Dr. Baust stated "There are a number of potential cancers that could benefit from this new treatment paradigm including prostate and breast cancer. To this end, the incidence of prostate cancer has a significant impact on men's health and quality of life in the United States with more than 240,000 new cases diagnosed and nearly 40,000 deaths reported annually. As cancer has an age-related incidence, the number of patients diagnosed and deaths are projected to increase ~7% annually as the population over the age of 65 increases. Management and treatment of this population represents a significant financial burden. Nationally, the overall financial commitment to treat prostate cancer, based on current treatment options, is projected to reach ~$50 billion. As such, there is a compelling need to develop new highly effective, low risk, minimally invasive, economical approaches to treat prostate cancer. It is our belief that *CryoInject*™ and *CryoPellets*™ may provide for such a technology and approach down the road."

About CPSI Biotech - CPSI Biotech is a research and technology development company specializing in the area of low temperature medicine and medical devices. In support of the innovative development strategy, CPSI runs parallel research programs focusing in the life (cell & molecular biology) and engineering sciences. Through thisintegrated multi-disciplinary approach, CPSI scientists and engineers are currently pursuing the development of several different technologies focused in the use of low temperatures to eradicate tumor tissue. In addition to corporate R&D activities, CPSI maintains a strong linkage to Binghamton University and hosts undergraduate laboratory sessions and internships where students can work directly in the laboratory as well as interact with the company officers and scientists to learn more about careers in biotechnology.

Disclosure Notice: The information contained in this release is as of June 3, 2013. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI's technologies do not have regulatory clearance for commercial sale and are currently intended for "Research Use Only".

This release may contain forward-looking statements that may impact the matters, including but not limited to, CPSI's ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defendable, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and the ability to raise the capital required to accomplish the foregoing.

Contacts

CPSI Biotech Contact:
John M Baust, Ph.D., President & Lead Scientist
Kristi Snyder, Ph.D., Director of Operations
607-687-8701
contact@cpsibiotech.com